Resources
The AMR Action Fund Appoints Bill Burns as Board Chair
This move brings the Fund, launched one year ago, one step closer to delivering 2 to 4 new antibiotics to...
Read MoreAntibiotic resistance in the patient with cancer
The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.
Legislation Aims to Jump Start Antibiotic Development
Before joining the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Duffy served as executive vice president and chief scientific officer at Melinta Therapeutics, a developer of new antibiotics.
Drug-resistant Infections Led to $1.9 Billion in Health Care Costs
Superbugs that are resistant to existing antibiotics already take an enormous toll on health-care systems around the world.
Governments fall behind in race to stem antimicrobial resistance
When drugmaker AstraZeneca closed down its research and development centre in Bangalore six years ago, some of the local scientists managed to find new jobs at a nearby biotech start-up. Since then, they have been working to tackle a problem which is causing concern among doctors in India and around the world: increasing resistance to antibiotics undermining treatments.
A research and development fund for new treatments for bacteria...
The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.
It's time to fix the antibiotic market...
We need to keep developing new antibiotics to make sure we can keep protecting ourselves from ever-evolving bacteria
If Scientists Don't Develop New Antibiotics Soon, 'We'll All Be...
Before joining the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Duffy served as executive vice president and chief scientific officer at Melinta Therapeutics, a developer of new antibiotics.
Biopharmaceutical Representative Joins New Antibiotic Resistanc...
Superbugs that are resistant to existing antibiotics already take an enormous toll on health-care systems around the world.
Countries brace for ‘silent tsunami’ of antibiotic-resistan...
When drugmaker AstraZeneca closed down its research and development centre in Bangalore six years ago, some of the local scientists managed to find new jobs at a nearby biotech start-up. Since then, they have been working to tackle a problem which is causing concern among doctors in India and around the world: increasing resistance to antibiotics undermining treatments.
